Non-human animals having a humanized programmed cell death 1 gene

A gene and cell technology, applied in the field of non-human animals with humanized programmed cell death 1 gene, can solve problems such as downregulation

Active Publication Date: 2017-04-26
REGENERON PHARM INC
View PDF18 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This grand challenge is partly due to the ability of cancer cells to evade the surveillance mechanisms of the immune system, which in part leads to the suppression and / or downregulation of antitumor immunity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Non-human animals having a humanized programmed cell death 1 gene
  • Non-human animals having a humanized programmed cell death 1 gene
  • Non-human animals having a humanized programmed cell death 1 gene

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0213] Example 1 Humanization of Endogenous Programmed Cell Death 1 (Pdcd1) Gene

[0214] This example illustrates an exemplary method for humanizing the endogenous Pdcd1 gene encoding programmed cell death protein 1 (PD-1 ) in a non-human mammal, such as a rodent (eg, mouse). The methods described in this example can be used to humanize the endogenous Pdcd1 gene of a non-human animal using any human sequence or combination of human sequences (or sequence fragments) as described. In this example, ~883 bp of exon 3 comprising exon 2, intron 2 and the first 71 bp of the human PDCD1 gene presented in GenBank accession number: NM_005018.2 (SEQ ID NO: 23) was used Human DNA fragments were used to humanize the endogenous Pdcd1 gene. The targeting vector used to humanize the genetic material encoding the extracellular N-terminal IgV region of the endogenous Pdcd1 gene was used technology (see, eg, US Patent No. 6,586,251 and Valenzuela et al., 2003, Nature Biotech. 21(6):652-659; i...

Embodiment 2

[0221] Example 2 Expression of humanized PD-1 on activated T cells

[0222] This example demonstrates that a non-human animal (eg, a rodent) modified to contain a humanized Pdcd1 gene according to Example 1 expresses a humanized PD-1 protein on the surface of activated lymphocytes. In this example, activated T cells from mice heterozygous for the humanization of the endogenous Pdcd1 gene as described in Example 1 were stained with an anti-PD-1 antibody to determine the role of PD-1 in segregating Expression in stimulated T cells from wild-type and humanized mice.

[0223] Briefly, spleens were harvested from wild-type mice and mice heterozygous humanized for the endogenous Pdcd1 gene as described in Example 1, and processed into single cell suspensions by mechanical dissociation. Cells were washed in culture medium (RPMI, supplemented with 10% FBS) and washed at 1×10 6 / mL resuspension, and plate 200 μL (200,000 cells) in a 96-well plate. Cells in selected cells were stimul...

Embodiment 3

[0225] Example 3 In vivo efficacy of PD-1 regulators

[0226] This example demonstrates that non-human animals (e.g., rodents) modified to contain a humanized Pdcd1 gene according to Example 1 can be used in in vivo assays to screen for PD-1 modulators (e.g., anti-PD-1 antibodies) and Various properties are determined, for example, inhibition of tumor growth and / or killing of tumor cells. In this example, several anti-PD-1 antibodies were screened in humanized heterozygous mice against the endogenous Pdcd1 gene as described in Example 1 to determine the optimal antibody dose and Extent of Anti-PD-1 Antibody Mediated Tumor Cell Killing.

[0227] Briefly, mice were evenly divided according to body weight into five treatment or control groups for Study 1 (n=5 / group), and eight treatment or control groups for Study 2 (n=5 / group) and five treatment groups or control groups for study 3 (n=7 / group). On day zero, mice were anesthetized by isoflurane inhalation, and then a suspensio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Programmed cell death 1 (Pdcd1) gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Pdcd1 gene so that said non-human animals express a PD-1 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).

Description

[0001] Cross references to related patent applications [0002] This application claims the benefit of U.S. Provisional Application Nos. 62 / 014,181, filed June 19, 2014, 62 / 086,518, filed December 2, 2014, and priority to 62 / 138,221, filed March 25, 2015 rights and interests, the entire contents of these applications are incorporated herein by reference. [0003] The sequence listing is incorporated by reference [0004] The sequence listing is a 23KB ASCII text file named 31969_SEQ.txt created on June 4, 2015, submitted to the US Patent and Trademark Office via EFS-Web, and incorporated herein by reference. Background technique [0005] Despite the continued focus and major improvements in medical research and development on cancer immunotherapy, cancer remains a major challenge in the global healthcare industry. This grand challenge is partly due to the ability of cancer cells to evade the surveillance mechanisms of the immune system, which in part leads to the suppression...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(China)
IPC IPC(8): A01K67/027C07K14/705A61K39/395A61K45/06A61P35/00
CPCA01K67/0275A61K39/3955A61K45/06C07K14/70521C07K16/2818C07K16/2827A01K2267/01A01K2227/105A61K2039/505A61K2039/545C07K2317/92C07K2317/76C07K2317/21C07K2317/31A61K2300/00A01K2207/15A01K2217/072C07K14/4747C07K2319/00C07K2319/02C07K2319/03A01K67/0278A01K2267/0331A61P35/00C12Q2600/106C07K16/2803A01K2217/05C12Q1/6886G01N2333/70503C12Q2600/158G01N2500/10G01N2333/57A61K49/0008G01N33/5038C07K14/70503C12N15/85C07K14/435C12N15/8509C07K14/705C12N5/0606G01N33/5088
InventorE·布罗瓦A·O·穆吉卡K-M·V·赖A·J·莫菲
OwnerREGENERON PHARM INC